172 related articles for article (PubMed ID: 34229620)
1. Gastrointestinal manifestations of synthetic cannabinoids: a retrospective cohort study.
Hakimian D; Benson AA; Khoury T; Massarwa M; Israel S; Salameh S; Gershinsky Y; Shapira B; Muszkat M
BMC Gastroenterol; 2021 Jul; 21(1):274. PubMed ID: 34229620
[TBL] [Abstract][Full Text] [Related]
2. Acute intoxication caused by three common synthetic cannabinoids: The experience of a large, urban, tertiary care hospital.
Shopan N; Scolnik D; Hassoun E; Firsow A; Volkov I; Glatstein M
Am J Emerg Med; 2023 Nov; 73():7-10. PubMed ID: 37572408
[TBL] [Abstract][Full Text] [Related]
3. Critical Illness Secondary to Synthetic Cannabinoid Ingestion.
Kourouni I; Mourad B; Khouli H; Shapiro JM; Mathew JP
JAMA Netw Open; 2020 Jul; 3(7):e208516. PubMed ID: 32687586
[TBL] [Abstract][Full Text] [Related]
4. Psychotic Disorders in Patients Who Use Synthetic Cannabinoids.
Skryabin VY; Vinnikova MA
J Psychiatr Pract; 2019 Nov; 25(6):485-490. PubMed ID: 31821228
[TBL] [Abstract][Full Text] [Related]
5. [Spice intoxication and hyperglycemia].
Elena-González A; Cuadros-Tito P; Esteban-Gutiérrez G
An Sist Sanit Navar; 2020 Apr; 43(1):87-91. PubMed ID: 31999272
[TBL] [Abstract][Full Text] [Related]
6. Emergence of new classes of recreational drugs-synthetic cannabinoids and cathinones.
Khullar V; Jain A; Sattari M
J Gen Intern Med; 2014 Aug; 29(8):1200-4. PubMed ID: 24553958
[TBL] [Abstract][Full Text] [Related]
7. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications.
Castaneto MS; Gorelick DA; Desrosiers NA; Hartman RL; Pirard S; Huestis MA
Drug Alcohol Depend; 2014 Nov; 144():12-41. PubMed ID: 25220897
[TBL] [Abstract][Full Text] [Related]
8. Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis.
Filippini G; Minozzi S; Borrelli F; Cinquini M; Dwan K
Cochrane Database Syst Rev; 2022 May; 5(5):CD013444. PubMed ID: 35510826
[TBL] [Abstract][Full Text] [Related]
9. Synthetic Cannabinoid-Associated Multiple Organ Failure: Case Series and Literature Review.
Armstrong F; McCurdy MT; Heavner MS
Pharmacotherapy; 2019 Apr; 39(4):508-513. PubMed ID: 30811628
[TBL] [Abstract][Full Text] [Related]
10. A survey of synthetic cannabinoid consumption by current cannabis users.
Gunderson EW; Haughey HM; Ait-Daoud N; Joshi AS; Hart CL
Subst Abus; 2014; 35(2):184-9. PubMed ID: 24821356
[TBL] [Abstract][Full Text] [Related]
11. Jellybean-Induced Intoxication: A Case Series of Unintentional Synthetic Cannabinoid Exposure in Children and Adults.
Az A
Am J Forensic Med Pathol; 2023 Dec; 44(4):358-361. PubMed ID: 37432966
[TBL] [Abstract][Full Text] [Related]
12. Adverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and Withdrawal.
Cooper ZD
Curr Psychiatry Rep; 2016 May; 18(5):52. PubMed ID: 27074934
[TBL] [Abstract][Full Text] [Related]
13. Psychiatric comorbidity associated with synthetic cannabinoid use compared to cannabis.
Bassir Nia A; Medrano B; Perkel C; Galynker I; Hurd YL
J Psychopharmacol; 2016 Dec; 30(12):1321-1330. PubMed ID: 27462088
[TBL] [Abstract][Full Text] [Related]
14. Retrospective Chart Review of Synthetic Cannabinoid Intoxication with Toxicologic Analysis.
Sud P; Gordon M; Tortora L; Stripp M; Borg D; Berman A
West J Emerg Med; 2018 May; 19(3):567-572. PubMed ID: 29760857
[TBL] [Abstract][Full Text] [Related]
15. Synthetic Cannabinoid Abuse in Adolescents: A Case Series.
Besli GE; Ikiz MA; Yildirim S; Saltik S
J Emerg Med; 2015 Nov; 49(5):644-50. PubMed ID: 26293411
[TBL] [Abstract][Full Text] [Related]
16. "Spice" and "K2" herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans.
Gunderson EW; Haughey HM; Ait-Daoud N; Joshi AS; Hart CL
Am J Addict; 2012; 21(4):320-6. PubMed ID: 22691010
[TBL] [Abstract][Full Text] [Related]
17. Dermatological aspects of synthetic cannabinoid addiction.
Inci R; Kelekci KH; Oguz N; Karaca S; Karadas B; Bayrakci A
Cutan Ocul Toxicol; 2017 Jun; 36(2):125-131. PubMed ID: 27028361
[TBL] [Abstract][Full Text] [Related]
18. Cannabinoids and synthetic cannabinoids as a cause of death: Trends and their healthcare implications.
Suriaga A; Tappen RM; Aston ER; Chiang-Hanisko L; Newman D
J Nurs Scholarsh; 2023 May; 55(3):623-636. PubMed ID: 36250599
[TBL] [Abstract][Full Text] [Related]
19. Characteristics and Treatment of Patients with Clinical Illness Due to Synthetic Cannabinoid Inhalation Reported by Medical Toxicologists: A ToxIC Database Study.
Monte AA; Calello DP; Gerona RR; Hamad E; Campleman SL; Brent J; Wax P; Carlson RG;
J Med Toxicol; 2017 Jun; 13(2):146-152. PubMed ID: 28397128
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology, Clinical Effects, and Therapeutic Potential of Cannabinoids for Gastrointestinal and Liver Diseases.
Maselli DB; Camilleri M
Clin Gastroenterol Hepatol; 2021 Sep; 19(9):1748-1758.e2. PubMed ID: 32673642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
